Original Article
Diagnostic Delay in Patients with Eosinophilic Gastritis and/or Duodenitis: A Population-Based Study

https://doi.org/10.1016/j.jaip.2020.12.054Get rights and content
Under a Creative Commons license
open access

Background

Eosinophilic gastritis and/or eosinophilic duodenitis (EG/EoD) is characterized by persistent symptoms and elevated eosinophils in the gastrointestinal tract. Limited disease awareness and lack of diagnostic guidelines suggest that patients may remain undiagnosed or endure diagnostic delay.

Objective

To characterize the path to diagnosis for patients with EG/EoD in a representative population.

Methods

In this observational cohort study, 4108 eligible patients diagnosed with EG/EoD between 2008 and 2018 were identified in an administrative claims database in the United States. Patient medical claim history was analyzed to describe events related to diagnosis.

Results

Mean year from symptom presentation to diagnosis of EG/EoD was 3.6; factors contributing to diagnostic delay included delayed gastroenterologist referral, delayed esophagogastroduodenoscopy (EGD), and lack of biopsy collection and/or histopathologic evaluation. Missed diagnosis on index EGD occurred in 38.2% of patients, resulting in a mean increase of 1.6 years in time to diagnosis versus patients diagnosed on index EGD. Patients presented with nonspecific symptoms and 44.3% were diagnosed with another gastrointestinal condition before EG/EoD diagnosis. Independent predictors of >2-year diagnostic delay included adult age; prior diagnosis of irritable bowel syndrome, functional dyspepsia, or gastric/peptic ulcer; use of other procedures such as colonoscopy; presence of edema; and history of certain allergic diseases.

Conclusions

This study found that patients with EG/EoD experienced an average of 3.6 years between initial symptom presentation and diagnosis and revealed several factors contributing to diagnostic delay. We hope that these findings, together with heightened awareness and standardization of diagnostic guidelines, will improve the diagnostic journey of patients with EG/EoD.

Key words

Eosinophilic gastrointestinal disease
Eosinophilic enteritis
Eosinophilic gastroenteritis
Eosinophilic esophagitis

Abbreviations used

CPT
Current Procedural Terminology
EG
Eosinophilic gastritis
EGD
Esophagogastroduodenoscopy
EGID
Eosinophilic gastrointestinal disease
EoD
Eosinophilic duodenitis
EoE
Eosinophilic esophagitis
hpf
High-powered field
IBS
Irritable bowel syndrome
ICD
International Classification of Diseases
OR
Odds ratio

Cited by (0)

Allakos, Inc. was the sponsor and funding source of the study.

Conflicts of interest: M. Chehade received research support from the National Institutes of Health (R01-AI140133, U54-AI117804), American Partnership for Eosinophilic Disorders/American Academy of Allergy, Asthma, and Immunology, Shire, Regeneron, Allakos, AstraZeneca, and Danone; consulting fees from Shire/Takeda, Regeneron, Allakos, Adare, AstraZeneca, Sanofi, and Bristol Myers Squibb; lecture honoraria from Nutricia, Medscape, and Vindico. A. P. Kamboj is a full-time employee of Allakos, Inc.; owns stocks and stock options; and is named on patents for the company. D. Atkins received consulting fees from Allakos and DBV and lecture honoraria from Seahec. L. T. Gehman is a full-time employee of Allakos, Inc. and owns stocks and stock options for the company.